Overview

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Status:
RECRUITING

Trial end date:
2032-05-31

Target enrollment:

Participant gender:

Summary

This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).

Phase:

PHASE1

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

Aclaris Therapeutics, Inc.
United States Department of Defense

Treatments:

Capecitabine
Denosumab
Zoledronic Acid